Results 91 to 100 of about 5,687 (195)

Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma [PDF]

The combination of the Bruton tyrosine kinase inhibitor ibrutinib with bendamustine-rituximab for first-line treatment of mantle cell lymphoma (MCL) prolonged progression-free survival (PFS), but without improvement in overall survival (OS), likely ...
Belada David, Borbényi Zita, Cheah Chan Y, Chu Michael P, Dreyling Martin, Fogliatto Laura, Forsyth Cecily, Jurczak Wojciech, Kahl Brad S, Kollaborációs szervezet: ECHO investigators, Kryachok Iryna, Lesley Robin, Li Yufu, Morawska Marta, Paludo Jonas, Patti Caterina, Ramadan Safaa, Rule Simon, Salek David, Sancho Juan-Manuel, Song Yuqin, Wang Michael, Zhang Jingyang   +22 more
core   +1 more source

A phase II study of Bruton’s tyrosine kinase inhibition for the prevention of anaphylaxis

The Journal of Clinical Investigation, 2023
BACKGROUND IgE-mediated anaphylaxis is a potentially fatal systemic allergic reaction for which there are no currently FDA-approved preventative therapies.
Ragha V. Suresh, Collin Dunnam, Dhananjay Vaidya, Robert A. Wood, Bruce S. Bochner, Donald W. MacGlashan Jr., Melanie C. Dispenza   +6 more
doaj   +1 more source

Covalent Bruton tyrosine kinase inhibitors across generations: A focus on zanubrutinib [PDF]

Bruton tyrosine kinase (BTK), the primary target of BTK inhibitors, is a key enzyme in the proliferation and survival pathway of neoplastic B-cells. BTK inhibitors are approved in many hematologic malignancies: chronic lymphocytic leukaemia, mantle cell ...
Broccoli, Alessandro, Danesi, Romano, Del Re, Marzia, Zinzani, Pier Luigi   +3 more
core   +1 more source

Kinetics of lymphocytosis in naïve chronic lymphocytic leukemia patients treated with covalent Bruton's tyrosine kinase inhibitors: An Italian multicenter real-life experience [PDF]

N/
Autore, Francesco, Bellesi, Silvia, Fresa, Alberto, Galli, Eugenio, Innocenti, Idanna, Laurenti, Luca, Mosca, Antonio, Sangiorgi, Eugenio, Stirparo, Luca, Tomasso, Annamaria   +9 more
core   +1 more source

Acalabrutinib-based regimens in frontline or relapsed/refractory higher-risk CLL: Pooled analysis of 5 clinical trials [PDF]

: Before targeted therapies, patients with higher-risk chronic lymphocytic leukemia (CLL) defined as del(17p) and/or TP53 mutation (TP53m), unmutated immunoglobulin heavy chain variable region genes (uIGHV), or complex karyotype (CK) had poorer prognosis
Butturini, Anna Maria, Byrd, John C, Davids, Matthew S, Emeribe, Ugochinyere, Eyre, Toby A, Ghia, Paolo, Jurczak, Wojciech, Palhares de Miranda, Paulo A, Shahkarami, Mina, Sharman, Jeff P, Siddiqi, Tanya, Woyach, Jennifer A   +11 more
core   +1 more source

Ibrutinib and acalabrutinib use and risk of incident atrial fibrillation: a propensity-matched analysis

Experimental Hematology & Oncology
Ibrutinib and acalabrutinib are both associated with an increased risk of atrial fibrillation (AF); however, the comparative risk of AF between these 2 BTK inhibitors remains largely unknown.
Joachim Alexandre, Jonaz Font, Thibault Lenormand, Sylvain Chantepie, Hippolyte Bardet, Gandhi Damaj, Charles Dolladille, Damien Legallois, Angélique Da-Silva, Paul Milliez, Arnaud Bisson, Laurent Fauchier   +11 more
doaj   +1 more source

Mutational profile in previously treated patients with chronic lymphocytic leukemia progression on acalabrutinib or ibrutinib [PDF]

Chronic lymphocytic leukemia (CLL) progression during Bruton tyrosine kinase (BTK) inhibitor treatment is typically characterized by emergent B-cell receptor pathway mutations.
Benrashid, Samon, Byrd, John C, de Bruin, Gerjan, De Jesus, Gary, Ghia, Paolo, Illés, Árpád, Jones, Daniel, Jurczak, Wojciech, Kater, Arnon P, Lai, Richard, Lai, Tzung-Huei, Long, Susan, Mohamed, Nehad, Munugalavadla, Veerendra, Robak, Tadeusz, Rule, Simon, Seymour, John F, Woyach, Jennifer A   +17 more
core   +1 more source

Cardiotoxicity from bruton tyrosine kinase inhibitors (BTKi)—an analysis of an administrative health claims database

Cardio-Oncology
Background First generation Bruton tyrosine kinase inhibitors (BTKi) such as ibrutinib have been associated with cardiovascular toxicities. Newer generation BTKi (e.g.,acalabrutinib and zanabrutinib) have been associated with lower incidence of ...
Srilakshmi Vallabhaneni, Srinath Adusumalli, Jingyi Wu, Peter W. Groeneveld, James Gerson, Rupal P. O’Quinn   +5 more
doaj   +1 more source

Upfront Management of Blastoid Variant Mantle Cell Lymphoma: Making the Case for 2nd/3rd-Generation Bruton Tyrosine Kinase Inhibitor-Based Therapies. [PDF]

INTRODUCTION: Blastoid variant-mantle cell lymphoma (BV-MCL) represents an aggressive subset of patients with no established standard of care treatment approach.
Brem, Elizabeth, Ciurea, Stefan, Doh, Jean, Griffin, Shawn, Kongtim, Piyanuch, Lee, Benjamin, Liu, Jenny   +6 more
core   +1 more source

Effect of Acalabrutinib in Combination with Bendamustine plus Rituximab on Survival Endpoints in Older Patients with Mantle Cell Lymphoma: Insights from the ECHO Trial

healthbook TIMES. Oncology Hematology
Mantle cell lymphoma (MCL) is a rare and often aggressive type of non-Hodgkin lymphoma that predominantly affects older adults and presents significant treatment challenges due to its clinical complexity and poor prognosis.
Adrian Schmidt
doaj   +1 more source